AMPH (Amphastar Pharmaceuticals, Inc.) Stock Financials & Earnings

AMPHAmphastar Pharmaceuticals, Inc.

Mkt Cap$894M

Revenue (TTM)$720M

Net Income (TTM)$98M

EPS (TTM)$2.03

Free Cash Flow (TTM)$0

Gross Margin49.5%

Op. Margin19.5%

Net Margin13.6%

FCF Margin0.0%

P/S Ratio (TTM)1.2x

P/E Ratio (TTM)9.1x

YoY Rev Growth-1.3%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$140M	$74M	$33M
Q2 23	$146M	$73M	$37M
Q3 23	$181M	$108M	$73M
Q4 23	$178M	$96M	$54M
Q1 24	$172M	$87M	$48M
Q2 24	$182M	$95M	$55M
Q3 24	$189M	$102M	$57M
Q4 24	$187M	$87M	$45M
Q1 25	$171M	$85M	$37M
Q2 25	$174M	$86M	$42M
Q3 25	$192M	$99M	$25M
Q4 25	$183M	$86M	$36M

Revenue Breakdown

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q1 23	$20M	$13M	$7M
Q2 23	$17M	$12M	$7M
Q3 23	$17M	$13M	$6M
Q4 23	$20M	$13M	$9M
Q1 24	$14M	$16M	$9M
Q2 24	$18M	$13M	$9M
Q3 24	$21M	$15M	$9M
Q4 24	$18M	$13M	$10M
Q1 25	$20M	$16M	$12M
Q2 25	$20M	$14M	$10M
Q3 25	$22M	$39M	$12M
Q4 25	$23M	$16M	$10M

Revenue Segments

Quarter	Other revenues	Product revenues, net	Product	Product and Service, Other
Q3 23	$29M	$152M	—	—
Q2 24	$3M	$179M	—	—
Q3 24	—	—	$189M	$2M

Revenue by Geography

Quarter	China	France	United States
Q1 23	$127K	$2M	$138M
Q2 23	$1M	$635K	$144M
Q3 23	$833K	$2M	$178M
Q4 23	$2M	$459K	$175M
Q1 24	$403K	$2M	$170M
Q2 24	$2M	$4M	$176M
Q3 24	$178K	$5M	$187M
Q4 24	$2M	$9M	$175M
Q1 25	$81K	$8M	$163M
Q2 25	$299K	$7M	$167M
Q3 25	$2M	$10M	$180M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$177M	$18M	$195M
Q2 23	$151M	$17M	$168M
Q3 23	$267M	$33M	$300M
Q4 23	$144M	$113M	$257M
Q1 24	$201M	$88M	$290M
Q2 24	$190M	$28M	$218M
Q3 24	$192M	$58M	$250M
Q4 24	$152M	$70M	$222M
Q1 25	$183M	$54M	$237M
Q2 25	$188M	$44M	$232M
Q3 25	$217M	$62M	$279M
Q4 25	$170M	$113M	$283M

Shares Outstanding

Revenue Per Employee

Revenue / Employee